MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jama.2023.12905

Медицинская библиотека · JAMA · 2023

Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries.

Yoo Sang Gune K, Chung Grace S, Bahendeka Silver K, Sibai Abla M, Damasceno Albertino, Farzadfar Farshad, Rohloff Peter, Houehanou Corine, Norov Bolormaa, Karki Khem B, Azangou-Khyavy Mohammadreza, Marcus Maja E, Aryal Krishna K, Brant Luisa C C, Theilmann Michaela, Cífková Renata, Lunet Nuno, Gurung Mongal S, Mwangi Joseph Kibachio, Martins Joao, Haghshenas Rosa, Sturua Lela, Vollmer Sebastian, Bärnighausen Till, Atun Rifat, Sussman Jeremy B, Singh Kavita, Saeedi Moghaddam Sahar, Guwatudde David, Geldsetzer Pascal, Manne-Goehler Jennifer, Huffman Mark D, Davies Justine I, Flood David

СтатьяМногоцентровое исследованиеПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

IMPORTANCE

Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD. To guide efforts to mitigate the global CVD burden, there is a need to understand current levels of aspirin use for secondary prevention of CVD.

OBJECTIVE

To report and evaluate aspirin use for secondary prevention of CVD across low-, middle-, and high-income countries.

DESIGN, SETTING, AND

PARTICIPANTS

Cross-sectional analysis using pooled, individual participant data from nationally representative health surveys conducted between 2013 and 2020 in 51 low-, middle-, and high-income countries. Included surveys contained data on self-reported history of CVD and aspirin use. The sample of participants included nonpregnant adults aged 40 to 69 years.

EXPOSURES: Countries' per capita income levels and world region; individuals' socioeconomic demographics.

MAIN OUTCOMES AND MEASURES: Self-reported use of aspirin for secondary prevention of CVD.

RESULTS

The overall pooled sample included 124 505 individuals. The median age was 52 (IQR, 45-59) years, and 50.5% (95% CI, 49.9%-51.1%) were women. A total of 10 589 individuals had a self-reported history of CVD (8.1% [95% CI, 7.6%-8.6%]). Among individuals with a history of CVD, aspirin use for secondary prevention in the overall pooled sample was 40.3% (95% CI, 37.6%-43.0%). By income group, estimates were 16.6% (95% CI, 12.4%-21.9%) in low-income countries, 24.5% (95% CI, 20.8%-28.6%) in lower-middle-income countries, 51.1% (95% CI, 48.2%-54.0%) in upper-middle-income countries, and 65.0% (95% CI, 59.1%-70.4%) in high-income countries.

CONCLUSION AND RELEVANCE: Worldwide, aspirin is underused in secondary prevention, particularly in low-income countries. National health policies and health systems must develop, implement, and evaluate strategies to promote aspirin therapy.

Для цитирования: Yoo Sang Gune K, Chung Grace S, Bahendeka Silver K, Sibai Abla M, Damasceno Albertino, Farzadfar Farshad, Rohloff Peter, Houehanou Corine, Norov Bolormaa, Karki Khem B, Azangou-Khyavy Mohammadreza, Marcus Maja E, Aryal Krishna K, Brant Luisa C C, Theilmann Michaela, Cífková Renata, Lunet Nuno, Gurung Mongal S, Mwangi Joseph Kibachio, Martins Joao, Haghshenas Rosa, Sturua Lela, Vollmer Sebastian, Bärnighausen Till, Atun Rifat, Sussman Jeremy B, Singh Kavita, Saeedi Moghaddam Sahar, Guwatudde David, Geldsetzer Pascal, Manne-Goehler Jennifer, Huffman Mark D, Davies Justine I, Flood David. Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries.. JAMA. 2023. DOI: 10.1001/jama.2023.12905.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.